Company Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1992 |
| IPO Date | May 23, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,400 |
| CEO | Kyle Gano |
Contact Details
Address: 12780 El Camino Real San Diego, California 92130 United States | |
| Phone | 858 617 7600 |
| Website | neurocrine.com |
Stock Details
| Ticker Symbol | NBIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000914475 |
| CUSIP Number | 64125C109 |
| ISIN Number | US64125C1099 |
| Employer ID | 33-0525145 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kyle W. Gano Ph.D. | Chief Executive Officer and Director |
| Matthew C. Abernethy CPA | Chief Financial Officer |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine |
| Jane Sorensen | Head of Investor Relations |
| Darin M. Lippoldt Esq. | Chief Legal Officer and Corporate Secretary |
| Julie S. Cooke | Chief Human Resources Officer |
| Eric S. Benevich | Chief Commercial Officer |
| David Warren Boyer | Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 144 | Filing |
| Aug 28, 2024 | 8-K | Current Report |